Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus oral antidepressants for major depressive disorder with suicidal ideation
ChiCTR2000041232Phase 4Recruiting
- Sponsor
- The Affiliated Brain Hospital of Guangzhou Medical University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD), sponsored by The Affiliated Brain Hospital of Guangzhou Medical University. Primary endpoint: Columbia Suicide Severity Rating Scale at day 33. Started Jan 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2000041232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041232.